UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 92

Sortiert nach

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Nature communications, 2020-01, Vol.11 (1), p.660-660, Article 660

2020

Link zum Volltext

Verfügbarkeit prüfen

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

PloS one, 2017-07, Vol.12 (7), p.e0179431

2017

Link zum Volltext

Verfügbarkeit prüfen

Enhanced antibody half-life improves in vivo activity

Nature biotechnology, 2010-02, Vol.28 (2), p.157-159

2010

Link zum Volltext

Verfügbarkeit prüfen

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2914-2925

2021

Link zum Volltext

Verfügbarkeit prüfen

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002024

2021

Link zum Volltext

Verfügbarkeit prüfen

Soluble TNF mediates the transition from pulmonary inflammation to fibrosis

PloS one, 2006-12, Vol.1 (1), p.e108-e108

2006

Link zum Volltext

Verfügbarkeit prüfen

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

Journal of translational autoimmunity (Online), 2022-01, Vol.5, p.100152-100152, Article 100152

2022

Link zum Volltext

Verfügbarkeit prüfen

Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection

Journal of Immunology, 2007-08, Vol.179 (3), p.1872-1883

2007

Link zum Volltext

Verfügbarkeit prüfen

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases

Journal of translational autoimmunity (Online), 2021-01, Vol.4, p.100103-100103, Article 100103

2021

Link zum Volltext

Verfügbarkeit prüfen

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Journal for immunotherapy of cancer, 2022-04, Vol.10 (4), p.e004419

2022

Link zum Volltext

Verfügbarkeit prüfen

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Journal for immunotherapy of cancer, 2021-11, Vol.9 (11), p.e003480

2021

Link zum Volltext

Verfügbarkeit prüfen

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development

Frontiers in pain research (Lausanne, Switzerland), 2021-08, Vol.2, p.695962-695962

2021

Link zum Volltext

Verfügbarkeit prüfen

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A224-A225

2020

Link zum Volltext

Verfügbarkeit prüfen

Transgene-mediated cosuppression in the C. elegans germ line

Genes & development, 2000-07, Vol.14 (13), p.1578-1583

2000

Link zum Volltext

Verfügbarkeit prüfen

Abstract 123: Enhanced anti-tumor activity of the combination of entinostat and NKTR214 in renal and colon cancer tumor models

Cancer research (Chicago, Ill.), 2018, Vol.78 (13_Supplement), p.123-123

2018

Link zum Volltext

Verfügbarkeit prüfen

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Cancer discovery, 2019-06, Vol.9 (6), p.711-721

2019

Link zum Volltext

Verfügbarkeit prüfen

CD38+ cell depletion with TAK-079 reduces arthritis in a cynomolgus collagen-induced arthritis (CIA) model

The Journal of immunology (1950), 2017-05, Vol.198 (1_Supplement), p.127-127.17

2017

Link zum Volltext

Verfügbarkeit prüfen

NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells

The Journal of clinical investigation, 2021-10, Vol.131 (19), p.1-14

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.7488-7490

2022

Link zum Volltext

Verfügbarkeit prüfen

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

The Journal of pharmacology and experimental therapeutics, 2019-08, Vol.370 (2), p.182

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3085-3085

2018

Link zum Volltext

Verfügbarkeit prüfen

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.2567-2567

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2256: Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2256-2256

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(92)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(48)
Life Sciences & Biomedicine
(30)
Animals
(24)
Humans
(21)
Female
(15)
Mice
(15)
Optics
(14)
Physical Sciences
(14)
Immunology
(11)
Cytokines
(9)
Lymphocytes
(9)
Mice, Inbred C57bl
(9)
Oncology
(9)
Male
(8)
Immunotherapy
(7)
Tumors
(7)
Cell Line, Tumor
(6)
Interleukin-2 - Analogs & Derivatives
(6)
Science & Technology - Other Topics
(6)
Technology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

Enhanced antibody half-life improves in vivo activity

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy

Soluble TNF mediates the transition from pulmonary inflammation to fibrosis

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus

Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection

NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

In vivo and in vitro Characterization of a Partial Mu Opioid Receptor Agonist, NKTR-181, Supports Future Therapeutic Development

368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors

Transgene-mediated cosuppression in the C. elegans germ line

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Abstract 123: Enhanced anti-tumor activity of the combination of entinostat and NKTR214 in renal and colon cancer tumor models

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

CD38+ cell depletion with TAK-079 reduces arthritis in a cynomolgus collagen-induced arthritis (CIA) model

NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells

A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

Efficacy and immune modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a CD122-biased immune agonist with PD1 blockade in murine pancreatic tumors

TAK-659 in combination with NKTR-214 and anti-PD-1 therapy leads to complete and sustained tumor regression and immune memory in pre-clinical syngeneic models

Abstract 2256: Combination of neoantigen DNA plasmid vaccine VB10.NEO and NKTR-214, a CD122-biased immunostimulatory cytokine, induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models

Suchergebnisse filtern